Publications (18)29.57 Total impact
-
Article: Unusual case of orbital apex syndrome after chalazion excision.
[show abstract] [hide abstract]
ABSTRACT: Orbital apex syndrome represents a heterogeneous group of disorders. It involves damage to the third, fourth and sixth nerves and the ophthalmic division of the fifth cranial nerve, and results in optic neuropathy. An 80-year-old man presented to our emergency clinic with left acute visual loss and three-day history of ocular pain. His medical and ophthalmic history involved diagnosis of lung cancer and chalazion excision two weeks prior to presentation. There was total left ophthalmoplegia, vision was 'no light perception' and he had a relative afferent pupillary defect. An urgent computed tomography scan of the orbits showed sub-periosteal abscess on the lateral wall of the orbit extending to the optic canal. The muscle cone was unaffected. The diagnosis was orbital apex syndrome. He underwent urgent drainage of the abscess and Staphylococcus aureus was identified with Gram stain. He was systemically administered intravenous antibiotics and steroids. His visual acuity and ophthalmoplegia improved rapidly 12 hours after surgery. Prompt diagnosis and treatment in cases of orbital apex syndrome, especially in immunocompromised patients, is important to prevent visual and life-threatening complications.Clinical and Experimental Optometry 09/2012; · 1.05 Impact Factor -
Article: Vascular Endothelial Growth Factor Inhibitors for Treatment of Corneal Neovascularization: A Meta-Analysis.
[show abstract] [hide abstract]
ABSTRACT: PURPOSE:: To evaluate the therapeutic effect of bevacizumab (Avastin) on corneal neovascularization (NV). METHODS:: Systematic review and meta-analysis of the literature was performed. Seven eligible clinical human studies and 18 eligible experimental animal studies examining the effectiveness of bevacizumab treatment on corneal NV were included in the meta-analysis. Pertinent publications were identified through a systematic search of PubMed. All references of relevant reviews and eligible articles were also screened, and data were extracted from each eligible study. The random-effects model (of DerSimonian and Laird) was used to combine the results from the selected studies. Heterogeneity was explored using available data. Publication bias was also assessed. RESULTS:: A significant reduction of corneal neovascularized area was seen in clinical human studies, with a pooled reduction of 36% [95% confidence interval (CI), 18%-54%] overall, of 32% (95% CI, 10%-54%) for subconjunctival anti-vascular endothelial growth factor injections, and 48% (95% CI, 32%-65%) for topical treatment. Pooled mean change in best-corrected visual acuity showed an improvement in best-corrected visual acuity by 0.04. The summary standardized mean difference in animal studies indicated a statistically significant reduction in the area of corneal NV when treated with bevacizumab compared with the control group by -1.71 (95% CI, -2.12 to -1.30). The subtotal pooled standardized mean differences were -1.83 (95% CI, -2.38 to -1.28) for subconjunctival anti-vascular endothelial growth factor injections and -1.50 (95% CI, -1.88 to -1.12) for topical treatment. CONCLUSION:: Our results suggest that both topical and subconjunctival bevacizumab achieve significant reduction in the area of corneal NV. This meta-analysis provides an evidential basis for the new therapeutic concept of treating corneal NV with antiangiogenic therapy.Cornea 06/2012; · 1.73 Impact Factor -
Article: Unusual case of silent corneal perforation in a human immunodeficiency virus-infected patient.
Clinical and Experimental Optometry 04/2011; 94(6):589-91. · 1.05 Impact Factor -
Article: Effect of aminoguanidine on the conjunctival histamine and nitrite levels in experimental conjunctivitis.
[show abstract] [hide abstract]
ABSTRACT: Histamine and nitric oxide (NO) play pivotal roles in ocular surface hypersensitivity reactions, whereas the activity of their metabolic enzymes diamine oxidase (DAO) and NO synthase (NOS) may affect their function. This study aimed at investigating the effects of ocular administration of aminoguanidine (AMG), a multiple action DAO and NOS inhibitor, on the conjunctival histamine and nitrite levels in a model of experimental conjunctivitis. AMG, at 0.81, 81 or 81×10(3) μM, was instilled into the lower conjunctival fornix of normal and compound 48/80 (C48/80)-challenged eyes of male Wistar rats in the absence or presence of 40 mg/mL disodium cromoglycate. Histamine and nitrite were quantified in the conjunctival homogenate and lavage fluid 45 min and 6 h postchallenge, respectively. AMG induced no significant alterations in basal histamine and nitrite levels in the normal rat eye. In experimental conjunctivitis, AMG failed to modify the reduction in histamine content and partially circumvented the increases in nitrite levels observed during the early and late phase reactions, respectively. In the presence of disodium cromoglycate, AMG significantly increased the levels of both proinflammatory mediators in the normal rat eye. The data suggested that DAO may not be the main route of in situ histamine catabolism in the normal and C48/80-challenged rat conjunctiva, whereas NOS contributes to the phenotypic alterations observed in mast cell-dependent conjunctivitis. Mast cell stabilizing agents and AMG-modulated systems seem to interact through yet undefined mechanisms in the different phases of ocular hypersensitivity reactions.Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics 04/2011; 27(2):137-42. · 1.46 Impact Factor -
Article: Presumed sterile corneal ulcer following autologous limbal stem cell and amniotic membrane transplantation: report of an unusual complication.
Clinical and Experimental Optometry 02/2011; 94(5):484-7. · 1.05 Impact Factor -
Article: Macular hole formation following phacoemulsification cataract surgery.
Clinical and Experimental Optometry 01/2011; 94(1):112-4. · 1.05 Impact Factor -
Article: Intraoperative complication during phacoemulsification in patient with epidermolysis bullosa.
[show abstract] [hide abstract]
ABSTRACT: We report the case of a 56-year-old woman with known recessive dystrophic epidermolysis bullosa and an unremarkable ocular history who experienced an extensive corneal epithelial blister during phacoemulsification cataract surgery. To our knowledge, this is the first report of this complication. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.Journal of cataract and refractive surgery 01/2011; 37(1):198-200. · 2.75 Impact Factor -
Article: Orbital metastasis secondary to breast cancer mimicking thyroid-associated ophthalmopathy.
Clinical and Experimental Optometry 09/2010; 93(5):368-9. · 1.05 Impact Factor -
Article: Exemestane-induced corneal epithelial changes.
[show abstract] [hide abstract]
ABSTRACT: We report a case of corneal epithelial changes that occurred as ocular side effects of treatment with exemestane, a selective steroidal aromatase inhibitor. A 55-year-old woman presented to our outpatient department for routine eye examination. Clinical examination revealed bilateral corneal gray-white bands appearing as intraepithelial microcysts. Her past medical history included breast cancer, for which she underwent chemotherapy and subsequent treatment with exemestane. She was followed up for 1 year, during which the clinical picture of the cornea remained unchanged in both eyes and visual acuity remained unaffected. A causal connection seems to be possible between systemic treatment with exemestane and persisting corneal intraepithelial cysts.Cutaneous and Ocular Toxicology 09/2010; 29(3):209-11. · 0.91 Impact Factor -
Article: Peripheral ulcerative keratitis in a patient with systemic-onset juvenile idiopathic arthritis.
[show abstract] [hide abstract]
ABSTRACT: The recognition of ocular manifestations in juvenile idiopathic arthritis is critical. The authors report an unusual manifestation of corneal involvement in a 10-year-old girl with systemic-onset juvenile idiopathic arthritis who presented with unilateral peripheral ulcerative keratitis during arthritis exacerbation. Corneal inflammation was successfully managed with topical steroids, oral methylprednisolone, and methotrexate.Journal of Pediatric Ophthalmology & Strabismus 01/2010; 47 Online:e1-3. · 0.63 Impact Factor -
Article: The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration.
[show abstract] [hide abstract]
ABSTRACT: Our purpose was to evaluate the possible effect of intravitreal ranibizumab on the fellow untreated eye with choroidal neovascularization (CNV) and subfoveal scarring associated with age-related macular degeneration (AMD). A retrospective observational study was conducted. One hundred eighty-seven ranibizumab-treated patients diagnosed as having subfoveal CNV scarring in the untreated eye were compared with a control group of untreated unilateral subfoveal CNV scarring. Inclusion criteria concerning treated eyes in the ranibizumab group complied with the MARINA and ANCHOR studies. Demographic data, clinical course, visual acuity, fluorescein angiography and optical coherence tomography findings were evaluated. Clinical improvement was confirmed in 24% of the patients in the ranibizumab group and in only 12.9% of the controls. Improvement was noted as early as 2-4 months (2.83 + or - 0.75 months) after the initiation of treatment in the fellow eye compared with 33.25 + or - 9.43 months in the control group (p = 0.01; Mann-Whitney U test). Kaplan-Meier curves demonstrate the positive impact of ranibizumab on the visual acuity of the fellow untreated eye (p = 0.016; Log-Rank test). Ranibizumab might induce some therapeutic effect in selected cases of end-stage CNV scarring, which needs to be further examined. The VEGF levels in the compartments of the fellow eye of patients with age-related macular degeneration treated with ranibizumab need to be further evaluated.Ophthalmologica 08/2009; 223(6):383-9. · 1.42 Impact Factor -
Article: Corneal melt in lattice corneal dystrophy type II after cataract surgery.
[show abstract] [hide abstract]
ABSTRACT: We report a patient with lattice corneal dystrophy type II, also known as Meretoja syndrome or familial amyloidosis Finnish type, who developed a corneal melt 15 days after uneventful phacoemulsification. Despite conservative treatment, the corneal melt resulted in perforation. Uneventful penetrating keratoplasty was performed, but delayed graft epithelial healing was noticed postoperatively. Corneal button histopathological evaluation confirmed the initial clinical diagnosis. To our knowledge, this is the first reported case of corneal melt and perforation in a patient with lattice corneal dystrophy type II.Journal of Cataract [?] Refractive Surgery 02/2009; 35(1):185-9. · 2.26 Impact Factor -
Article: Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study.
[show abstract] [hide abstract]
ABSTRACT: The purpose of this study was to evaluate the pharmacokinetics of intravenously administered moxifloxacin, a fourth-generation fluoroquinolone, in different parts of the non-inflamed eye. Moxifloxacin was administered intravenously at a dose of 20mg/kg moxifloxacin over 30min. Sampling of peripheral blood, aqueous humour and vitreous was performed at standard time intervals post infusion once in each animal. Moxifloxacin levels were estimated by high-performance liquid chromatography with fluorescence detection. Mean serum concentrations were 3.43, 2.74, 1.48 and 1.12microg/mL at 0.5, 3, 6 and 24h after the end of drug infusion, respectively. Respective concentrations in aqueous humour were 2.44, 2.03, 1.30 and 1.09microg/mL and in vitreous body they were 1.68, 1.87, 1.78 and 1.15microg/mL. It is concluded that systemic administration of moxifloxacin in rabbits was accompanied by efficient penetration into both the aqueous humour and the vitreous body at concentrations well above the minimum inhibitory concentration for most causative pathogens of endophthalmitis. Further research is mandatory to clarify the clinical significance of these findings.International Journal of Antimicrobial Agents 11/2008; 33(2):160-2. · 4.13 Impact Factor -
Article: Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
[show abstract] [hide abstract]
ABSTRACT: To evaluate the effect of subconjunctival injection of bevacizumab on experimentally induced corneal neovascularization. Experimental animal study. Twelve New Zealand white rabbits were involved, divided equally into four groups. Only one eye per rabbit was used. Topical instillation of 10 microl 5% NaOH solution was used, under general anesthesia, to induce corneal neovascularization secondary to corneal alkali burn in groups 2, 3, and 4. A single dose of 3.75 mg (25 mg/ml) bevacizumab was injected subconjunctivally. Group 1 (control group 1) was neither cauterized nor treated. Group 2 (control group 2) received a sham injection of balanced salt solution on day 14. Group 3 was treated on day 14 (after corneal neovascularization had been established). Group 4 was treated on day 1. Digital photographs were obtained and analyzed during the entire 28-day procedure. The area of neovascularization and scarring were measured in terms of the percentage of corneal surface affected. On day 28, the difference of neovascularization between groups 2, 3, and 4 was found to be statistically significant at the .05 level (one-way analysis of variance [ANOVA]): group 4 (4.7%+/-3.1%)<group 3 (13.3%+/-2.3%)<group 2 (41.0%+/-3.6%; P<.05, Mann-Whitney U test). In group 3, the area of neovascularization decreased 14 days after treatment by 42%. Neovascularization was almost completely absent in group 4. The development of scarring was unaffected by bevacizumab (P>.1, one-way ANOVA). No side effects were noted. Subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit experimental model, especially if administered early.American Journal of Ophthalmology 04/2008; 145(3):424-431. · 4.22 Impact Factor -
Article: A male with polysyndactyly, linear skin defects and sclerocornea. Goltz syndrome versus MIDAS.
[show abstract] [hide abstract]
ABSTRACT: Focal dermal hypoplasia (FDH) or Goltz syndrome is a rare clinical syndrome presenting with cutaneous, skeletal, dental, ocular, central nervous system and soft-tissue defects. We report on a male infant with characteristic skin defects of the face, trunk and extremities, polysyndactyly and unusual ocular and brain findings. He had sclerocornea of the right eye, anterior persistent hyperplastic primary vitreous of the left eye and hydrocephalus. Clinical findings support the diagnosis of Goltz syndrome. The clinical picture of Goltz syndrome is compared with that of MIDAS syndrome.Clinical Dysmorphology 11/2002; 11(4):277-81. · 0.54 Impact Factor -
Article: Malignant ectomesenchymoma of the orbit in a child: Case report and review of the literature.
[show abstract] [hide abstract]
ABSTRACT: Malignant ectomesenchymoma is a rare soft tissue tumor of childhood composed of both mesenchymal and neuroectodermal elements. Reported sites of origin are head and neck, abdomen, perineum, scrotum, and extremities. A new case of an orbital ectomesenchymoma in a 7-year-old boy is presented. The clinical picture of the tumor, radiological findings, and its histopathologic and immunohistochemical characteristics are described. The patient was successfully treated with combined surgical resection and chemotherapy. All the other reported cases of malignant ectomesenchymoma with various sites of origin are also reviewed.Survey of Ophthalmology 47(4):368-74. · 2.35 Impact Factor -
Article: Vitrectomy for treatment of a lamellar hole in a patient with exudative macular degeneration: the role of vitreous traction elimination.
[show abstract] [hide abstract]
ABSTRACT: Lamellar macular hole (LMH) represents a well-defined clinical entity with variable pathophysiologic mechanisms and a controversial therapeutic approach. The purpose of the present work is to present a patient with an epiretinal membrane (ERM)-associated LMH on the background of exudative age-related macular degeneration (AMD) that was successfully managed with pars plana vitrectomy. Interventional case report. A 67-year-old man presented with progressive visual loss OS of 5 months' duration. He was diagnosed with an ERM-associated LMH with coexisting subretinal fluid arising by a neovascular membrane on the background of exudative AMD confirmed with fundus fluorescein angiography. He underwent a 3-port pars plana vitrectomy with ERM-internal limiting membrane peeling and gas tamponade (14% C3F8) for treatment of the LMH and ERM with a view to undergo anti-vascular endothelial growth factor treatment for the exudative AMD. Postoperative optical coherence tomography demonstrated complete closure of the LMH with simultaneous total subretinal fluid absorption that was maintained at the 2-month follow-up period. To our knowledge, this is the first report whereby pars plana vitrectomy in a patient with an ERM-associated LMH on the background of exudative AMD resulted in improvement of both clinical entities. The latter strengthens the role of vitreous traction elimination in exudative AMD and highlights the need for further research.European journal of ophthalmology 20(6):1086-8. · 0.96 Impact Factor -
Article: A rare case of peripheral ulcerative keratitis in temporal arteritis.
[show abstract] [hide abstract]
ABSTRACT: To present a case of peripheral ulcerative keratitis (PUK) that progressed to corneal perforation in the setting of recently diagnosed temporal arteritis. A 76-year-old man presented with a 2-week history of red eye and gradual loss of vision in the right eye. His medical history included recently diagnosed temporal arteritis without previous eye involvement. Clinical examination revealed severe peripheral corneal melting leading to corneal perforation. The patient was treated in the acute phase with topical dexamethasone drops and oral prednisolone. Perforation was sealed with cyanoacrylate glue. Azathioprine was also administered. Inflammation was resolved and his eye remains quiet. To our knowledge, this is the first reported case of PUK in the background of temporal arteritis.European journal of ophthalmology 19(5):866-9. · 0.96 Impact Factor
Top co-authors
Top Journals
Institutions
-
2008–2012
-
Attikon University Hospital
Athens, Attiki, Greece
-
-
2008–2011
-
Harokopion University of Athens
Athens, Attiki, Greece
-
